Centiva Capital, LP Madrigal Pharmaceuticals, Inc. Call Options Transaction History
Centiva Capital, LP
- $3.13 Billion
- Q1 2025
Call Options
2 transactions
Others Institutions Holding MDGL
# of Institutions
367Shares Held
23.3MCall Options Held
979KPut Options Held
459K-
Janus Henderson Group PLC London, X02.21MShares$662 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$630 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$607 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$598 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$593 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.13B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...